
    
      German APERIO® Hybrid Post- Market Clinical Follow-up Study

      APERIO® Hybrid PMCF Study- Thrombectomy device for flow restoration in vessels of patients
      experiencing acute ischemic stroke

      Study Type: prospective, multicenter, single-armed, open-label

      Participants: 13 participating centers in Germany planned

      PI: Dr. Christian Mathys, Evangelisches Krankenhaus Oldenburg, Germany

      Estimated Enrolment: 430 patients treated with APERIO® HYBRID Thrombectomy

      Device as a result of an acute stroke

      Follow up: 3 months

      Estimated Final Assessment: End of 2022
    
  